Zacks: Analysts Expect Denali Therapeutics Inc (NASDAQ:DNLI) Will Post Quarterly Sales of $18.39 Million

Brokerages forecast that Denali Therapeutics Inc (NASDAQ:DNLI) will report sales of $18.39 million for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Denali Therapeutics’ earnings, with the highest sales estimate coming in at $50.70 million and the lowest estimate coming in at $4.50 million. Denali Therapeutics reported sales of $125.68 million during the same quarter last year, which indicates a negative year-over-year growth rate of 85.4%. The business is scheduled to report its next earnings results on Tuesday, March 10th.

According to Zacks, analysts expect that Denali Therapeutics will report full year sales of $36.09 million for the current financial year, with estimates ranging from $22.00 million to $72.71 million. For the next year, analysts expect that the business will report sales of $66.51 million, with estimates ranging from $16.61 million to $175.00 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Denali Therapeutics.

DNLI has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a research report on Monday, January 13th. ValuEngine downgraded shares of Denali Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, January 28th. Goldman Sachs Group raised shares of Denali Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the company from $20.00 to $37.00 in a research report on Sunday, January 26th. Stifel Nicolaus initiated coverage on shares of Denali Therapeutics in a research report on Tuesday, February 18th. They issued a “hold” rating and a $26.00 target price for the company. Finally, Jefferies Financial Group initiated coverage on shares of Denali Therapeutics in a research report on Monday. They issued a “buy” rating and a $35.00 target price for the company. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $29.22.

Denali Therapeutics stock traded down $1.76 during mid-day trading on Monday, reaching $22.69. The company’s stock had a trading volume of 827,072 shares, compared to its average volume of 775,085. The company has a market capitalization of $2.35 billion, a price-to-earnings ratio of -31.96 and a beta of 2.04. Denali Therapeutics has a 12 month low of $14.24 and a 12 month high of $30.41. The business’s 50 day simple moving average is $23.27 and its 200 day simple moving average is $18.74. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.59 and a current ratio of 10.59.

In other news, insider Carole Ho sold 3,464 shares of Denali Therapeutics stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $20.01, for a total value of $69,314.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ryan J. Watts sold 21,268 shares of Denali Therapeutics stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $18.26, for a total transaction of $388,353.68. In the last three months, insiders sold 34,798 shares of company stock valued at $645,938. Insiders own 21.20% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Baillie Gifford & Co. lifted its stake in shares of Denali Therapeutics by 3.1% during the 4th quarter. Baillie Gifford & Co. now owns 7,590,247 shares of the company’s stock worth $132,221,000 after buying an additional 226,784 shares during the last quarter. State Street Corp lifted its stake in shares of Denali Therapeutics by 0.6% during the 4th quarter. State Street Corp now owns 1,602,182 shares of the company’s stock worth $27,910,000 after buying an additional 10,089 shares during the last quarter. Casdin Capital LLC lifted its stake in shares of Denali Therapeutics by 92.3% during the 4th quarter. Casdin Capital LLC now owns 1,250,000 shares of the company’s stock worth $21,775,000 after buying an additional 600,000 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Denali Therapeutics by 2.9% during the 4th quarter. Geode Capital Management LLC now owns 867,618 shares of the company’s stock worth $15,113,000 after buying an additional 24,847 shares during the last quarter. Finally, Pictet Asset Management Ltd. lifted its stake in shares of Denali Therapeutics by 3.8% during the 3rd quarter. Pictet Asset Management Ltd. now owns 767,357 shares of the company’s stock worth $11,756,000 after buying an additional 28,009 shares during the last quarter. Institutional investors own 73.01% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Further Reading: What is a Derivative?

Get a free copy of the Zacks research report on Denali Therapeutics (DNLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit